NO20080937L - Substituerte-3-sulfonylindazolderivater som 5-hydroksytryptamin-6-ligander - Google Patents
Substituerte-3-sulfonylindazolderivater som 5-hydroksytryptamin-6-liganderInfo
- Publication number
- NO20080937L NO20080937L NO20080937A NO20080937A NO20080937L NO 20080937 L NO20080937 L NO 20080937L NO 20080937 A NO20080937 A NO 20080937A NO 20080937 A NO20080937 A NO 20080937A NO 20080937 L NO20080937 L NO 20080937L
- Authority
- NO
- Norway
- Prior art keywords
- hydroxytryptamine
- ligands
- substituted
- sulfonylindazole
- derivatives
- Prior art date
Links
- -1 Substituted-3-sulfonylindazole Chemical class 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70831505P | 2005-08-15 | 2005-08-15 | |
| PCT/US2006/030965 WO2007021711A2 (fr) | 2005-08-15 | 2006-08-08 | Derives de 3-sulfonylindazole substitues en tant que ligands de 5-hydroxytryptamine-6 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20080937L true NO20080937L (no) | 2008-04-30 |
Family
ID=37668440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20080937A NO20080937L (no) | 2005-08-15 | 2008-02-25 | Substituerte-3-sulfonylindazolderivater som 5-hydroksytryptamin-6-ligander |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7723329B2 (fr) |
| EP (1) | EP1931640A2 (fr) |
| JP (1) | JP5146766B2 (fr) |
| KR (1) | KR20080039994A (fr) |
| CN (1) | CN101282938A (fr) |
| AR (1) | AR057756A1 (fr) |
| AU (1) | AU2006280091A1 (fr) |
| BR (1) | BRPI0614343A2 (fr) |
| CA (1) | CA2619010C (fr) |
| CR (1) | CR9734A (fr) |
| EC (1) | ECSP088189A (fr) |
| GT (1) | GT200600376A (fr) |
| IL (1) | IL189476A0 (fr) |
| NO (1) | NO20080937L (fr) |
| NZ (1) | NZ565872A (fr) |
| PE (1) | PE20070354A1 (fr) |
| RU (1) | RU2429231C2 (fr) |
| SA (1) | SA06270314B1 (fr) |
| TW (1) | TW200740766A (fr) |
| UA (1) | UA94053C2 (fr) |
| WO (1) | WO2007021711A2 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| JP2009523734A (ja) * | 2006-01-13 | 2009-06-25 | ワイス | ５−ヒドロキシトリプタミン受容体のためのリガンドとしてのスルホニル置換された１ｈ−インドール |
| WO2007120596A1 (fr) * | 2006-04-12 | 2007-10-25 | Wyeth | DÉRIVÉS DE DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE EN TANT QUE LIGANDS DE 5-HYDROXYTRYPTAMINE-6 |
| CN101421280A (zh) * | 2006-04-12 | 2009-04-29 | 惠氏公司 | 作为5-羟色胺-6配体的经取代二氢[1,4]噁嗪并[2.3.4-hi]吲唑衍生物 |
| WO2007120599A2 (fr) * | 2006-04-12 | 2007-10-25 | Wyeth | Dérivés de dihydro[1,4]oxazino[2,3,4-hi]indazole en tant que ligands de 5-hydroxytryptamine-6 |
| US20090012308A1 (en) * | 2007-06-13 | 2009-01-08 | Wyeth | Process for the manufacture of benzylsulfonylarenes |
| CN103102322B (zh) * | 2011-11-14 | 2016-02-24 | 上海交通大学 | 噁唑类化合物及其制备方法、药物组合物及其用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200001234T2 (tr) | 1997-11-04 | 2000-08-21 | Pfizer Products Inc. | Terapötik aktif bileşiklerde katelkolün indazol biyoisoster değişimi. |
| WO2001005758A2 (fr) | 1999-07-15 | 2001-01-25 | Nps Allelix Corp. | Composes heterocycliques destines au traitement de la migraine |
| EP1343756A2 (fr) * | 2000-11-02 | 2003-09-17 | Wyeth | 1-aryl- ou 1-alkylsulfonyl-heterocyclylbenzazoles en tant que ligands de 5-hydroxytryptamine-6 |
| ES2264994T3 (es) | 2000-12-22 | 2007-02-01 | Wyeth | Compuestos heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6. |
| EA200300717A1 (ru) | 2000-12-22 | 2003-12-25 | Уайт | Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов |
| TW593278B (en) | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| KR20030088508A (ko) | 2001-04-20 | 2003-11-19 | 와이어쓰 | 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴옥시-, -티옥시- 및 -아미노벤즈아졸 유도체 |
| PL366639A1 (en) | 2001-04-20 | 2005-02-07 | Wyeth | Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| RU2294932C2 (ru) * | 2001-06-07 | 2007-03-10 | Ф.Хоффманн-Ля Рош Аг | Новые производные индола со сродством к рецептору 5-ht6 |
| EP1403255A4 (fr) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | Inhibiteurs de rho kinase |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| TW200400177A (en) | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| JP4754821B2 (ja) | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物 |
| TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
| TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| JP2006505559A (ja) * | 2002-10-18 | 2006-02-16 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ６受容体親和性を持つ４−ピペラジニルベンゼンスルホニルインドール |
| EP1569638B1 (fr) * | 2002-12-03 | 2007-09-05 | F. Hoffmann-La Roche Ag | Indols aminoalkoxy utilises en tant que ligands du recepteur 5-ht6 pour le traitement de troubles du snc |
| WO2004074286A1 (fr) | 2003-02-14 | 2004-09-02 | Wyeth | Derives de heterocyclyl-3-sulfonylazaindole ou -azaindazole utilises comme ligands de la 5-hydroxytryptamine-6 |
| CN100422171C (zh) * | 2003-02-14 | 2008-10-01 | 惠氏公司 | 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑 |
| KR20060114022A (ko) | 2004-02-27 | 2006-11-03 | 에프. 호프만-라 로슈 아게 | 인다졸 유도체 및 그들을 함유하는 약학 조성물 |
| KR20080034497A (ko) | 2005-08-15 | 2008-04-21 | 와이어쓰 | 5-히드록시트립타민-6 리간드로서의 아지닐-3-설포닐인다졸유도체 |
-
2006
- 2006-08-08 CA CA2619010A patent/CA2619010C/fr not_active Expired - Fee Related
- 2006-08-08 CN CNA2006800374446A patent/CN101282938A/zh active Pending
- 2006-08-08 BR BRPI0614343-1A patent/BRPI0614343A2/pt not_active IP Right Cessation
- 2006-08-08 JP JP2008526995A patent/JP5146766B2/ja not_active Expired - Fee Related
- 2006-08-08 KR KR1020087006267A patent/KR20080039994A/ko not_active Ceased
- 2006-08-08 NZ NZ565872A patent/NZ565872A/en unknown
- 2006-08-08 WO PCT/US2006/030965 patent/WO2007021711A2/fr not_active Ceased
- 2006-08-08 EP EP06801007A patent/EP1931640A2/fr not_active Withdrawn
- 2006-08-08 UA UAA200801842A patent/UA94053C2/ru unknown
- 2006-08-08 RU RU2008105807/04A patent/RU2429231C2/ru not_active IP Right Cessation
- 2006-08-08 AU AU2006280091A patent/AU2006280091A1/en not_active Abandoned
- 2006-08-14 PE PE2006000984A patent/PE20070354A1/es not_active Application Discontinuation
- 2006-08-14 AR ARP060103549A patent/AR057756A1/es unknown
- 2006-08-14 GT GT200600376A patent/GT200600376A/es unknown
- 2006-08-14 US US11/504,350 patent/US7723329B2/en not_active Expired - Fee Related
- 2006-08-14 TW TW095129795A patent/TW200740766A/zh unknown
- 2006-09-09 SA SA6270314A patent/SA06270314B1/ar unknown
-
2008
- 2008-02-12 IL IL189476A patent/IL189476A0/en unknown
- 2008-02-15 EC EC2008008189A patent/ECSP088189A/es unknown
- 2008-02-15 CR CR9734A patent/CR9734A/es not_active Application Discontinuation
- 2008-02-25 NO NO20080937A patent/NO20080937L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1931640A2 (fr) | 2008-06-18 |
| CN101282938A (zh) | 2008-10-08 |
| CA2619010A1 (fr) | 2007-02-22 |
| RU2429231C2 (ru) | 2011-09-20 |
| CA2619010C (fr) | 2013-10-01 |
| RU2008105807A (ru) | 2009-09-27 |
| IL189476A0 (en) | 2008-08-07 |
| WO2007021711A3 (fr) | 2007-05-03 |
| US7723329B2 (en) | 2010-05-25 |
| AR057756A1 (es) | 2007-12-19 |
| GT200600376A (es) | 2007-03-29 |
| WO2007021711A2 (fr) | 2007-02-22 |
| PE20070354A1 (es) | 2007-04-04 |
| UA94053C2 (ru) | 2011-04-11 |
| CR9734A (es) | 2008-04-03 |
| KR20080039994A (ko) | 2008-05-07 |
| BRPI0614343A2 (pt) | 2011-03-22 |
| US20070037802A1 (en) | 2007-02-15 |
| TW200740766A (en) | 2007-11-01 |
| NZ565872A (en) | 2011-06-30 |
| JP2009504739A (ja) | 2009-02-05 |
| JP5146766B2 (ja) | 2013-02-20 |
| ECSP088189A (es) | 2008-04-28 |
| AU2006280091A1 (en) | 2007-02-22 |
| SA06270314B1 (ar) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20050007L (no) | 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander | |
| NO20050014L (no) | 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander | |
| WO2007142905A3 (fr) | Dérivés de 1-sulfonylindazolylamine et de 1-sulfonylindazolylamide en tant que ligands de la 5-hydroxytryptamine-6 | |
| NO20083057L (no) | Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer | |
| NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
| NO20082285L (no) | 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| NO20044763L (no) | 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander | |
| NO20081454L (no) | Met-kinaseinhibitorer | |
| MA32508B1 (fr) | Composes organiques | |
| NO20075082L (no) | Pyridin-3-karboksamidderivater som CB1-inversagonister | |
| NO20090295L (no) | Substituerte heteroarylderivater | |
| NO20053792L (no) | Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander | |
| EA200901488A1 (ru) | Замещенные имидазолопиридазины, как ингибиторы липидкиназы | |
| NO20093009L (no) | Kondensert ring heterocykel kinase modulatorer | |
| NO20082090L (no) | Pyridopyrimidinoninhibitorer av P13K alfa | |
| NO20083058L (no) | Cykloheksylsulfonamidderivater med H3 reseptor aktivitet | |
| NO20063449L (no) | Substituerte heterocykler og deres anvendelse | |
| NO20044764L (no) | 1-(aminoalkyl)-3-sulfonylindol og -indazolderivater som 5-hydroksytryptamin-6 ligander | |
| NO20080061L (no) | Imidazolyl-pyrimidinforbindelser for anvendelse til behandling av proliferative lidelser | |
| NO20084363L (no) | 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister | |
| NO20082939L (no) | Sykloheksyl piperasinyl metanon derivater og anvendelse av disse som histamin H3 reseptor modulatorer | |
| NO20092048L (no) | Nye benzamidderivater som bradykininantagonister | |
| NO20080553L (no) | Azinyl-3-sulfonylindazolderivater som 5-hydroksytrypyamin-6 ligander | |
| NO20065678L (no) | 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |